| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Francesco Franza, Gabriella Carpentieri, Serena De Guglielmo, Vincenzo Fasano, Nicoletta Fiorentino, Mariangela Perito, Barbara Solomita, Gianfranco Del Buon. Neurocognitive management of the primary negative symptoms of schizophrenia: a role of atypical antipsychotics. Psychiatria Danubina. vol 28. issue Suppl-1. 2019-11-20. PMID:27663826. |
neurocognitive management of the primary negative symptoms of schizophrenia: a role of atypical antipsychotics. |
2019-11-20 |
2023-08-13 |
Not clear |
| Julio Bobes, J Rejas, M Garcia-Garcia, F Rico-Villademoros, M P García-Portilla, M Madrigal, G Hernánde. Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study. Clinical drug investigation. vol 22. issue 9. 2019-11-20. PMID:29492855. |
the eire (estudio de investigaciön de resultados en esquizofrenia - outcomes research study in schizophrenia) study was initiated in order to assess the frequency of adverse reactions [extrapyramidal symptoms (eps), hyperprolactinaemia, sexual dysfunction and weight gain] caused by atypical antipsychotics and haloperidol in patients with schizophrenia during routine treatment in clinical practice. |
2019-11-20 |
2023-08-13 |
Not clear |
| Bo-Ra-Mi Kim, Tae-Jin Lee, Hye-Jae Lee, Bo-Hyun Park, Bong-Min Yan. Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea. Value in health regional issues. vol 1. issue 1. 2019-11-20. PMID:29702828. |
cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in south korea. |
2019-11-20 |
2023-08-13 |
Not clear |
| Bo-Ra-Mi Kim, Tae-Jin Lee, Hye-Jae Lee, Bo-Hyun Park, Bong-Min Yan. Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea. Value in health regional issues. vol 1. issue 1. 2019-11-20. PMID:29702828. |
this study assessed the cost-effectiveness of sertindole compared with existing atypical antipsychotics in the treatment of patients with schizophrenia in the south korean setting. |
2019-11-20 |
2023-08-13 |
Not clear |
| Vlado Jukic, Miro Jakovljevic, Igor Filipcic, Miroslav Herceg, Ante Silic, Tatjana Tomljanovic, Roman Zilbershtein, Rasmus C D Jensen, Michiel E H Hemels, Thomas R Einarso. Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia. Value in health regional issues. vol 2. issue 2. 2019-11-20. PMID:29702863. |
cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in croatia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Yanling Zhou, Guannan Li, Dan Li, Hongmei Cui, Yuping Nin. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study. Journal of psychopharmacology (Oxford, England). vol 32. issue 5. 2019-11-04. PMID:29493377. |
the long-term effects of dose reduction of atypical antipsychotics on cognitive function and symptomatology in stable patients with schizophrenia remain unclear. |
2019-11-04 |
2023-08-13 |
Not clear |
| Rhiannon Kamstra, Dominic Pilon, Patrick Lefebvre, Bruno Emond, Kruti Josh. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Current medical research and opinion. vol 34. issue 8. 2019-10-21. PMID:29452492. |
treatment patterns and medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. |
2019-10-21 |
2023-08-13 |
Not clear |
| Rhiannon Kamstra, Dominic Pilon, Patrick Lefebvre, Bruno Emond, Kruti Josh. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Current medical research and opinion. vol 34. issue 8. 2019-10-21. PMID:29452492. |
to compare treatment patterns and medicaid spending between schizophrenia patients initiating once-monthly paliperidone palmitate (pp1m) and oral atypical antipsychotics (oaas) within four comorbid populations: cardiovascular disease (cvd), diabetes, hypertension and obesity. |
2019-10-21 |
2023-08-13 |
Not clear |
| Wallace Breno Barbosa, Juliana de Oliveira Costa, Lívia Lovato Pires de Lemos, Rosângela Maria Gomes, Helian Nunes de Oliveira, Cristina Mariano Ruas, Francisco de Assis Acurcio, Corrado Barbui, Marion Bennie, Brian Godman, Augusto Afonso Guerr. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. Applied health economics and health policy. vol 16. issue 5. 2019-10-08. PMID:30051254. |
costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in brazil. |
2019-10-08 |
2023-08-13 |
Not clear |
| Britta Stapel, Irina Sieve, Christine S Falk, Stefan Bleich, Denise Hilfiker-Kleiner, Kai G Kah. Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells. Journal of psychiatric research. vol 105. 2019-09-10. PMID:30216787. |
second-generation atypical antipsychotics are currently first-line drugs in the treatment of schizophrenia and are also used as augmentation strategies in treatment-resistant major depression. |
2019-09-10 |
2023-08-13 |
human |
| Britta Stapel, Irina Sieve, Christine S Falk, Stefan Bleich, Denise Hilfiker-Kleiner, Kai G Kah. Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells. Journal of psychiatric research. vol 105. 2019-09-10. PMID:30216787. |
our results suggest that atypical antipsychotics directly influence immune cell function and thereby highlight the importance to factor in potential side effects of drugs routinely used in treatment of schizophrenia and major depression on inflammatory processes when considering anti-inflammatory drug therapy as an additional treatment option. |
2019-09-10 |
2023-08-13 |
human |
| Claire Ainswort. Assessing the robustness of direct meta-analysis in the presence of heterogeneity. Journal of comparative effectiveness research. vol 7. issue 10. 2019-09-09. PMID:30130972. |
to assess robustness of findings in recent systematic reviews of atypical antipsychotics in schizophrenia patients in the presence of heterogeneity. |
2019-09-09 |
2023-08-13 |
Not clear |
| Peifan Li, Yiming Wang, Xingde Liu, Zhen Zhou, Jun Wang, Haiyan Zhou, Lei Zheng, Lixia Yan. Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling. BMC pharmacology & toxicology. vol 20. issue 1. 2019-09-09. PMID:30755277. |
there is evidence that atypical antipsychotics (aps) increase risk of osteoporosis in schizophrenia patients, however the mechanism is unclear. |
2019-09-09 |
2023-08-13 |
human |
| Yi-Lung Chen, Kun-Po Chen, Chih-Chiang Chiu, Ming-Hong Tai, For-Wey Lun. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC psychiatry. vol 18. issue 1. 2019-09-04. PMID:30509308. |
early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. |
2019-09-04 |
2023-08-13 |
Not clear |
| Yi-Lung Chen, Kun-Po Chen, Chih-Chiang Chiu, Ming-Hong Tai, For-Wey Lun. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC psychiatry. vol 18. issue 1. 2019-09-04. PMID:30509308. |
the aims of this study were to explore the relationship between early reduction in psychotic symptoms and the ultimate response in patients with schizophrenia treated by atypical antipsychotics, and to determine the best time to switch or maitain the regimen. |
2019-09-04 |
2023-08-13 |
Not clear |
| Emanuele F Osimo, Marie Juliette Goujon, Jesus Perez, Graham K Murra. Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia? BMJ case reports. vol 12. issue 3. 2019-07-29. PMID:30936353. |
can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia? |
2019-07-29 |
2023-08-13 |
Not clear |
| Gabriela Guilherme Monte, João V Nani, Marina Rosseto de Almeida Campos, Caroline Dal Mas, Lucas Augusto Negri Marins, Lucas Gelain Martins, Ljubica Tasic, Marcelo A Mori, Mirian A F Hayash. Impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode Caenorhabditis elegans: Putative animal model for studying the pathways correlated to schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 92. 2019-06-27. PMID:30578843. |
impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode caenorhabditis elegans: putative animal model for studying the pathways correlated to schizophrenia. |
2019-06-27 |
2023-08-13 |
caenorhabditis_elegans |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Toshio Moritani, Masataka Taguri, Yoshio Hirayas. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. BMC psychiatry. vol 18. issue 1. 2019-06-25. PMID:30016952. |
accordingly, to clarify the interindividual differences in the adverse effects of specific atypical antipsychotics in schizophrenia, we investigated the association between ans dysfunction and atp-binding cassette transport sub-family b member 1 (abcb1) gene polymorphisms in patients with schizophrenia. |
2019-06-25 |
2023-08-13 |
Not clear |
| Yu P Sivola. [Typical and atypical antipsychotics: how significant are the differences?] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 118. issue 11. 2019-06-05. PMID:30585617. |
it is believed that atypical antipsychotics are less likely to cause extrapyramidal disorders and have a more significant effect on the negative symptoms of schizophrenia compared to typical drugs. |
2019-06-05 |
2023-08-13 |
Not clear |
| Xueli Zhang, Yi Zhao, Yamin Liu, Yang Yuan, Hua Shao, Xiao Zhen. Regulation of obesity-associated metabolic disturbance by the antipsychotic drug olanzapine: Role of the autophagy-lysosome pathway. Biochemical pharmacology. vol 158. 2019-06-03. PMID:30291862. |
metabolic disturbance is commonly observed in schizophrenia patients, and the metabolic impacts of atypical antipsychotics such as olanzapine (ola) have received much attention. |
2019-06-03 |
2023-08-13 |
mouse |